These results suggest that modulation of p38/MAPKMAP4 phosphorylation signaling may identify a novel therapeutic target to attenuate proteinuria and renal fibrosis in patients with diabetic nephropathy (Li et al., 2022). Here, MAPK1 is linked to diabetic kidney disease.